High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis.

Autor:	Pedersen JL; School of Life Sciences, Faculty of Science University of Technology Sydney Sydney NSW Australia., Barry SE; Centenary Institute The University of Sydney Sydney NSW Australia.; South Australian Tuberculosis Services Royal Adelaide Hospital. Adelaide Australia., Bokil NJ; School of Life Sciences, Faculty of Science University of Technology Sydney Sydney NSW Australia., Ellis M; Centenary Institute The University of Sydney Sydney NSW Australia., Yang Y; Pathogen Biology and Medical Immunological Department Ningxia Medical University Yinchuan China., Guan G; Infectious Disease Hospital of Ningxia Yinchuan China., Wang X; Pathogen Biology and Medical Immunological Department Ningxia Medical University Yinchuan China., Faiz A; School of Life Sciences, Faculty of Science University of Technology Sydney Sydney NSW Australia., Britton WJ; Centenary Institute The University of Sydney Sydney NSW Australia., Saunders BM; School of Life Sciences, Faculty of Science University of Technology Sydney Sydney NSW Australia.; Centenary Institute The University of Sydney Sydney NSW Australia.
Jazyk:	angličtina
Zdroj:	Clinical & translational immunology [Clin Transl Immunology] 2021 Jun 22; Vol. 10 (6), pp. e1298. Date of Electronic Publication: 2021 Jun 22 (Print Publication: 2021).
DOI:	10.1002/cti2.1298
Abstrakt:	Objectives: Non-sputum-based tests to accurately identify active tuberculosis (TB) disease and monitor response to therapy are urgently needed. This study examined the biomarker capacity of a panel of plasma proteins alone, and in conjunction with a previously identified miRNA signature, to identify active TB disease. Methods: The expression of nine proteins (IP-10, MCP-1, sTNFR1, RANTES, VEGF, IL-6, IL-10, TNF and Eotaxin) was measured in the plasma of 100 control subjects and 100 TB patients, at diagnosis (treatment naïve) and over the course of treatment (1-, 2- and 6-month intervals). The diagnostic performance of the nine proteins alone, and with the miRNA, was assessed. Results: Six proteins were significantly up-regulated in the plasma of TB patients at diagnosis compared to controls. Receiver operator characteristic curve analysis demonstrated that IP-10 with an AUC = 0.874, sensitivity of 75% and specificity of 87% was the best single biomarker candidate to distinguish TB patients from controls. IP-10 and IL-6 levels fell significantly within one month of commencing treatment and may have potential as indicators of a positive response to therapy. The combined protein and miRNA panel gave an AUC of 1.00. A smaller panel of only five analytes (IP-10, miR-29a, miR-146a, miR-99b and miR-221) showed an AUC = 0.995, sensitivity of 96% and specificity of 97%. Conclusions: A novel combination of miRNA and proteins significantly improves the sensitivity and specificity as a biosignature over single biomarker candidates and may be useful for the development of a non-sputum test to aid the diagnosis of active TB disease. Competing Interests: The authors report no conflicts of interest with regard to this publication. (© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF